Remove 2001 Remove 2013 Remove Clinical Trials Remove Terpenes
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).

article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development efforts. Shlomi Raz.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). Only one article appeared in the MJA in 2000 and again in 2001. MJA, 16 December 2013). 17), Medical Journal of Australia ( n ?